GSK reported a similar state of affairs Wednesday. Sales of its RSV vaccine Arexvy declined 69% year over year due to lower demand “related to a more limited recommendation ... for individuals ...

Vaccines sales declined 3% in 2024, reflecting pressures on Arexvy and Shingrix in the U.S. However, Arexvy remains the market leader, and international uptake is gaining momentum. Emily Field ...

Vaccine sales fell 14% (-11% at constant currency) to 2.21 billion pounds, primarily impacted by lower demand for Arexvy related to a more limited ACIP recommendation in the U.S. and channel ...

After a blockbuster burst onto the market last year, sales of the RSV vaccine Arexvy nosedived this season. In a similar pattern already seen in the third quarter, Arexvy sales in the fourth ...

Vaccine sales fell 14% to £2.21B, with Arexvy sales down 70%, while Specialty Medicines grew 14% to £3.29B, and HIV drug revenue rose. Brand New Membership Level: Benzinga Trade Alerts Vaccine ...

Meanwhile, vaccine sales slipped by 4% for the year, driven by a sharp drop for its Arexvy lung disease treatment. Operating profits dropped by 40% to £4 billion due to a £1.8 billion settlement ...

Vaccine sales reflects the challenges we've seen from external pressures in the U.S. and China for Arexvy and Shingrix. Going forward, we expect these to continue in 2025, but equally remain ...

U.S. health officials in June narrowed Arexvy's patient recommendation to a smaller age range and more at-risk patients. On the contrary, its specialty-medicines sales are expected to increase by ...

Meanwhile, vaccine sales slipped by 4% for the year, driven by a sharp drop for its Arexvy lung disease treatment. Explore the key data from our strong 2024 performance. Operating profits dropped ...

Vaccine sales faced challenges due to external pressures in the U.S. and China, impacting Arexvy and Shingrix. The introduction of the Inflation Reduction Act is expected to have a GBP150 million to ...

A key therapeutic point is to avoid re-traumatising investors, as GSK did fairly recently with respiratory syncytial virus jab Arexvy. The company had promoted it as proof of how it is now able to ...